BioSpace News Archive

Company plans to activate at least 13 clinical sites for Alzheimer’s study and 18 clinical sites for head and neck cancer across the United States

Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., announced that its affiliate has entered into an agreement with Lochan LLC to develop the next-generation of Bausch + Lomb’s eyeTELLIGENCE™ clinical decision support software.

Bio-Techne Corporation announced it is joining the Cell and Gene Therapy Catapult process analytical technology consortium, which includes over 20 pharmaceutical companies, technology providers, therapy developers, and charities.

Foundation Medicine, Inc. and Natera, Inc., announced the launch of the research use version of FoundationOne®Tracker, Foundation Medicine’s personalized circulating tumor DNA monitoring assay.

ANANDA Scientific Inc., a biotech pharmaceutical company, and NYU Grossman School of Medicine announced that the first patient has been enrolled in a clinical trial evaluating Nantheia™ A1002N5S, an investigational drug using cannabidiol in ANANDA’s proprietary Liquid Structure™ delivery technology as a treatment for Post-Traumatic Stress Disorder symptoms and Neurocognitive Impairment in patients with PTSD and with PTSD comorbid with Traumatic Brain Injury.

Glaukos Corporation announced that the Therapeutic Goods Administration of Australia has granted regulatory approval for the PRESERFLO MicroShunt intended for the reduction of intraocular pressure in eyes of patients with primary open-angle glaucoma where IOP remains uncontrollable while on maximum tolerated medical therapy and/or where glaucoma progression warrants surgery.

AngioDynamics to Hold Fiscal Fourth Quarter and Fiscal Year 2021 Earnings Conference Call and Virtual Investor and Technology Day on July 13, 2021.

IMV Inc. will hold its 2021 annual and special meeting of shareholders (the “Meeting”) by way of a Virtual only meeting on Friday, June 18, 2021 at 11:00 am Eastern Daylight Time.

Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), announces that the Mydecine R&D team has made groundbreaking advances in psilocybin research with the discovery of over 40 compounds with pharmacological potential in mushrooms

According to the report, the global pericardiocentesis procedures market was valued at ~US$ 161 Mn in 2018 and is projected to expand at a high CAGR during the forecast period.